Shares of Chimerix, Inc. (CMRX) are trading up more than 7% in Wednesday’s pre-market session after the company announced that preliminary data for its investigational antiviral brincidofovir (BCV, CMX001) showed improved survival for patients with adenovirus in the open-label pilot portion of the Phase 3 AdVise Trial. Chimerix said the data will be presented at the annual meeting of the Infectious Diseases Society of America , IDWeek, on Saturday, October 11 at 10:50 a.m. EDT in Philadelphia, PA.
Chimerix, Inc., currently valued at $1.19B, has a median Wall Street price target of $33.00 with a high target of $37.00. Approximately 6,473,012 shares already changed hands during Tuesday’s trading session compared to the stock’s average daily volume of 546,262.
In the past 52 weeks, shares of the biopharmaceutical company have traded between a low of $12.96 and a high of $35.16 with the 50-day MA and 200-day MA located at $27.00 and $22.48 levels, respectively.Shares of CMRX trade at a P/B ratio of 5.84 and have a Relative Strength Index (RSI) and MACD indicator of 71.55 and +2.73, respectively.
CMRX currently prints a one year return of about 51.67% and a year-to-date return of around 119.92%.
Shares of SolarCity Corp. (SCTY) are up 2.87% to $56.20 in pre-market trade after it was reported that the company will begin offering customers who want to own their home solar systems rather than lease them or pay cash, 30-year loans with monthly payments based on how much electricity the systems produce.
The company said it will offer its loan program to customers in Arizona, California, Colorado, Connecticut, Hawaii, Massachusetts, New York and New Jersey, and ultimately plans to expand the product beyond its existing service territory.
On valuation-measures, shares of SolarCity have a price/book and price/sales ratio of 8.97 and 24.25, respectively. P/E to growth is 0.35, while t-12 profit margin is -21.35%. EPS registers at ($0.54). The company has a market cap of $5.06B and a median Wall Street price target of $93.50 with a high target of $98.00.
On trading-measure, SCTY has a beta of 5.66 and a short float of 20.69%. In the past 52 weeks, shares of the solar energy systems provider have traded between a low of $36.32 and a high of $88.35 with the 50-day MA and 200-day MA located at $66.07 and $62.30 levels, respectively.
SCTY currently prints a one year return of about 42.02% and a year-to-date loss of around 4.00%.
Allergan Inc. (AGN) is currently changing hands at $189, up 3.21%, following a Dow Jones report suggesting the Botox maker will get a new takeover bid from Valeant Pharmaceuticals (VRX) and Bill Ackman’s hedge fund Pershing Square for $191 a share, or $15 higher than the prior bid. The new offer comes at a time when Allergan’s is trying to make other deals that would fend off Valeant-Ackman takeover attempts. Separately, Reuters reports that Actavis plc is planning to approach Allergan again about a potential takeover deal. According to the report, Allergan would consider a takeover proposal that values the company at above $200 per share.
On valuation measures, AGN shares are currently priced at 43.80x this year’s forecasted earnings, which makes them expensive compared to the industry’s 8.35x earnings multiple. Ticker has a forward P/E of 22.57 and t-12 price-to-sales ratio of 8.07. EPS for the same period is $4.25.
In the past 52 weeks, shares of Irvine, California-based company, currently valued at $55.34B, have traded between a low of $88.34 and a high of $189.41 and are now at $189.00. Shares are up 106.82% year-over-year and 67.75% year-to-date.
GoPro, Inc. (GPRO), a manufactures of high-definition personal cameras, was downgraded by Piper Jaffray analysts to ‘Neutral’ from an ‘Overweight’ rating Wednesday. The firm maintained its 12-month-base case estimate at $90 a share. GoPro, shares were down 2.24% at $91.75 in pre-market trade, moving within a 52-week range of $28.65 to $98.47.
Intercept Pharmaceuticals, Inc. (ICPT) shares fell more than 6% on Wednesday after the company reported that that highly anticipated FLINT trial for OCA in NASH would not be presented at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting®), being held in Boston, Massachusetts from November 7-11, 2014. The company thinks investors will view the omission of this presentation negatively given the prior guidance by the company, the history of data dissemination from this trial, and the continued overhang of uncertainty about the full dataset.
In the past 52 weeks, shares of New York-based $4.73B market cap firm have traded between a low of $46.81 and a high of $497.00 and are now at $212.00. Shares are up 221.48% year-over-year and up 226.19% year-to-date.